Skip to main content

Amyris, Inc. (AMRS)

NASDAQ: AMRS · Delayed Price · USD
6.68
-0.10 (-1.47%)
At close: Nov 29, 2021 4:00 PM
6.52
-0.16 (-2.40%)
Pre-market:Nov 30, 2021 8:00 AM EST

Company Description

Amyris, Inc., a synthetic biotechnology company, operates in the clean health and beauty markets through its consumer brands and as a supplier of sustainable and natural ingredients in Europe, the United States, Asia, Brazil, and internationally.

It manufactures and sells products for the health and wellness, clean beauty, and flavor and fragrance markets. The company operates under the Amyris, Biofene, Biossance, Pipette, Purecane, and No Compromise trademarks.

Amyris, Inc. has a collaboration agreement with the Infectious Disease Research Institute to advance a novel ribonucleic acid vaccine platform, including accelerating the development of a COVID-19 vaccine.

The company was formerly known as Amyris Biotechnologies, Inc. and changed its name to Amyris, Inc. in June 2010. Amyris, Inc. was incorporated in 2003 and is headquartered in Emeryville, California.

Amyris, Inc.
Amyris Logo
CountryUnited States
Founded2003
IPO DateSep 28, 2010
IndustryChemicals
SectorMaterials
Employees595
CEOJohn Melo

Contact Details

Address:
5885 Hollis St Ste 100
Emeryville, California 94608-2405
United States
Phone510 450 0761
Websiteamyris.com

Stock Details

Ticker SymbolAMRS
ExchangeNASDAQ
Fiscal YearJanuary - December
Reporting CurrencyUS Dollars
CIK Code0001365916

Key Executives

NamePosition
John G. MeloPresident, Chief Executive Officer and Director
Hermanus KieftenbeldChief Financial Officer and Chief Administrative Officer
Eduardo AlvarezChief Operating Officer
Nicole KelseyGeneral Counsel and Secretary
Anthony HughesChief Accounting Officer
Peter DeNardoSenior Director of Investor Relations and Corporate Communications
Christine OforiChief People Officer
Charles KraftSenior Vice President of Global Manufacturing and Process Development
Caroline HadfieldPresident of Aprinnova
Jim IacoponiSenior Vice President of Nutrition Ingredients

Latest SEC Filings

DateTypeTitle
Nov 15, 20218-KCurrent report
Nov 8, 202110-QQuarterly report [Sections 13 or 15(d)]
Nov 8, 20218-KCurrent report
Sep 13, 20214Statement of changes in beneficial ownership of securities
Sep 7, 20218-KCurrent report
Sep 7, 2021424B7Prospectus [Rule 424(b)(7)]
Sep 3, 20214Statement of changes in beneficial ownership of securities
Sep 3, 20214Statement of changes in beneficial ownership of securities
Sep 3, 20214Statement of changes in beneficial ownership of securities
Sep 3, 20214Statement of changes in beneficial ownership of securities
View All SEC Filings